[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"uterine-neoplasms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:uterine-neoplasms":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,47,87,114,144,164,201,220],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100642313","evaluation-of-interactions-and-group-processes-in-multidisciplinary-tumor-boards-in-gynecologic-oncology-100642313",false,"NCT07645716","Evaluation of Interactions and Group Processes in Multidisciplinary Tumor Boards in Gynecologic Oncology","Group Dynamics Evaluation in ginecOlogic muLtidisciplinary Tumor boarDs","GOLD","Inclusion Criteria:\n\n* Physicians participating in the clinical decision-making process within ovarian and uterine cancer multidisciplinary tumor board meetings.\n* Participation in the full tumor board session.\n* Participation either in person or online.\n* Representation of at least one relevant specialty or role involved in the clinical decision-making process.\n\nExclusion Criteria:\n\n* Partial attendance at the ovarian and uterine cancer multidisciplinary tumor board session.\n* Trainees or other attendees not directly involved in the clinical decision-making process.\n* Physicians whose specialty contribution consists of occasional consultation for less than 50% of the study period.\n* Incomplete survey completion.\n* If more than one member represents the same specialty or role, participants with lower participation in the clinical decision-making process may be excluded.","ALL","18 Years",{"count":20,"type":21},400,"ESTIMATED","OBSERVATIONAL","Study Title Group Dynamics Evaluation in Gynecologic Multidisciplinary Tumor Boards - GOLD Study\n\nBackground and Rationale Multidisciplinary Tumor Boards are central to complex oncologic decision-making. In gynecologic oncology, clinical decisions often require the integration of knowledge from different specialties, including surgery, medical oncology, radiology, pathology, radiation oncology, and other relevant disciplines. These teams function not only as groups of specialists but also as collective decision-making systems, where communication, collaboration, information sharing, psychological safety, and group dynamics may influence the quality of clinical discussion and final recommendations.\n\nStudy Objective The GOLD Study aims to investigate the decision-making process and group dynamics within ovarian and uterine cancer Multidisciplinary Tumor Boards. The study will assess how communication patterns, collaboration, minority dissent, team cohesion, team learning, task interdependence, collective information processing, individual information processing, and psychological safety contribute to Tumor Board performance.\n\nStudy Design This is a single-center, prospective, longitudinal observational study involving physicians participating in ovarian and uterine cancer Multidisciplinary Tumor Boards, either in person or online.\n\nMethods At the end of each Tumor Board meeting, participating physicians will complete an online survey using Microsoft Forms. The questionnaire was developed within a scientific collaboration with the Department of Business and Management of LUISS Guido Carli University and includes validated measurement scales derived from the literature. In addition, data on team composition and participation will be collected for each meeting.\n\nStatistical Analysis Survey data and participation data will be analyzed using descriptive statistics, inferential methods, and social network analysis. Network measures such as density and centralization indices will be used to evaluate the structure of interactions and participation over time. Statistical analyses will be performed using Stata, R, and UCINET where appropriate.\n\nTarget Population and Sample Size The target population includes physicians involved in the clinical decision-making process during ovarian and uterine cancer Tumor Boards. A total of approximately 400 questionnaires is planned, based on the rule of thumb of at least 10 respondents per questionnaire variable.\n\nStudy Duration The expected study duration is six months.",[25,26],"Ovarian Neoplasms","Uterine Neoplasms",[25,26,28,29,30,31,32,33],"Multidisciplinary Tumor Board","Clinical Decision Making","Group Dynamics","Team Communication","Social Network Analysis","Surveys and Questionnaires","NOT_YET_RECRUITING","2026-06-09",{"date":37,"type":38},"2026-06-12","ACTUAL",{"date":40,"type":21},"2026-07-13",{"date":42,"type":21},"2027-03-31",{"name":44,"class":45},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":59,"conditions":60,"keywords":68,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":46},"100640491","measurement-of-urinary-hormones-in-patients-with-abnormal-uterine-bleeding-to-study-uterine-cancer-progression-100640491","NCT07581288","Measurement of Urinary Hormones in Patients With Abnormal Uterine Bleeding to Study Uterine Cancer Progression","Quantitative Hormonal Biomarkers of Uterine Cancer Progression in Patients With Abnormal Uterine Bleeding","MIRA","Inclusion Criteria:\n\n* 35 years and older\n* Have experienced AUB\n\nExclusion Criteria:\n\n* Currently pregnant or become pregnant during their participation\n* Previous surgeries impairing the menstrual cycle (e.g. hysterectomy, bilateral oophorectomy)\n* Currently or in the previous 3 months on medications that are known to impair or stimulate ovulation (e.g. oral contraceptives, ovulation stimulants, hormone replacement, etc.)","FEMALE","35 Years",{"count":58,"type":21},50,"The investigators will obtain urine hormone results and validated menstrual bleeding score from people experiencing abnormal uterine bleeding. The investigators will evaluate satisfaction and ease of use of Mira monitor. The investigators will measure recruitment rate, attrition and cycle collection completeness of data. The investigators will evaluate menstrual health literacy at baseline and at the conclusion of the study.",[61,62,26,63,64,65,66,67],"Uterine Bleeding","Uterine Cancer","Endometrial Cancer","Endometrial Hyperplasia","Endometrial Intraepithelial Neoplasia","Menstrual Cycle","Reproductive Endocrinology",[69,70,62,71,72,73,74,75,76,77],"Digital Health","Urinary Hormones","Abnormal Uterine Bleeding","Menstrual Cycle Tracking","At-home monitoring","Follicle Stimulating Hormone","Luteinizing Hormone","Estrogen","Progesterone","2026-05-06",{"date":80,"type":38},"2026-05-12",{"date":82,"type":21},"2026-05",{"date":84,"type":21},"2026-09",{"name":86,"class":45},"University of British Columbia",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":55,"minAge":4,"maxAge":4,"enrollmentInfo":94,"targetDuration":96,"studyType":22,"phases":4,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":46},"100622352","prospective-cohort-study-of-minimal-residual-diseasemrd-testing-for-early-recurrence-detection-in-endometrial-and-cervical-cancer-100622352","NCT07382505","Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer","Prospective Cohort to Evaluate the Prognostic and Early-Recurrence Detection Performance of Blood-based Minimal Residual Disease (MRD) Testing in Endometrial and Cervical Cancer","Inclusion Criteria:\n\n* Histologically confirmed endometrial cancer or cervical cancer.\n* Scheduled for or completed standard treatment (Surgery, Adjuvant therapy, or CCRT).\n* Provision of written informed consent for study participation and biospecimen collection\n\nExclusion Criteria:\n\n* Synchronous other malignancies (cancer requiring treatment within the last 5 years).\n* Persistent infection or bleeding tendency that makes repeated blood collection unsafe.\n* Inability to follow-up or communicate (e.g., due to geographic or cognitive reasons).\n* Any condition that the principal investigator deems inappropriate for the study.",{"count":95,"type":21},600,"2 Years","This study aims to evaluate the clinical performance of blood-based Minimal Residual Disease (MRD) testing using circulating tumor DNA (ctDNA) in patients with endometrial and cervical cancer. The researchers will investigate whether MRD detection can identify cancer recurrence earlier than current standard imaging or clinical methods (providing a \"lead time\"). Participants will undergo blood collection at specific time points, including at diagnosis, after surgery, and during regular follow-up visits. The study will also assess the correlation between MRD status and survival outcomes, such as Relapse-Free Survival (RFS) and Overall Survival (OS). The goal is to establish a foundation for personalized treatment strategies based on molecular monitoring.",[26,99],"Cervical Cancer",[63,99,101,102,103,104],"Minimal Residual Disease","MRD","Circulating Tumor DNA","Liquid Biopsy","2026-01-27",{"date":107,"type":38},"2026-02-02",{"date":109,"type":21},"2026-02-15",{"date":111,"type":21},"2027-12-31",{"name":113,"class":45},"Asan Medical Center",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":55,"minAge":18,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":124,"conditions":125,"keywords":128,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":46},"100589335","ultrasound-transformation-of-myomas-during-relugolix-estradiol-norethisterone-treatment-the-mysaturn-study-100589335","NCT06953076","Ultrasound Transformation of Myomas During Relugolix-Estradiol-Norethisterone Treatment: The MySaturn Study","MyomaS Aspect Transformation at Ultrasound During Relugolix Estradiol Noretisterone Treatment: MySaturn Study","MySaturn","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Pre-menopausal status.\n3. Ultrasound diagnosis of benign myometrial lesion.\n4. Symptomatic patients presenting with abnormal uterine bleeding (menorrhagia\u002Fmetrorrhagia).\n5. Availability of ultrasound images in digital format.\n\nExclusion Criteria:\n\n1. Patient refusal.\n2. Age \\\u003C 18 years.\n3. Postmenopausal women.\n4. Myometrial lesion ≤ 10 mm.\n5. Myometrial formation suspected of malignancy on ultrasound (e.g., STUMP - Uterine Leiomyosarcoma).\n6. Asymptomatic patients with uterine fibromatosis.\n7. Personal history of malignant or premalignant uterine neoplasia (e.g., STUMPs, leiomyosarcoma, atypical endometrial hyperplasia, endometrial carcinoma, cervical carcinoma).\n8. Patients with ovarian pathology.\n9. Patients currently undergoing treatment for another malignancy.\n10. Patients lacking available digital ultrasound images or whose image quality is insufficient to adequately characterize the target lesion's ultrasound features",{"count":123,"type":21},111,"Uterine fibroids are benign tumors originating from the uterine muscle, affecting up to 70% of women by their 50s. Risk factors include African descent, nulliparity, obesity, and diabetes. While many fibroids are asymptomatic, 25-50% of affected women experience symptoms like heavy menstrual bleeding, pelvic pain, and pressure-related issues. Accurate diagnosis and differentiation from rare malignant tumors (e.g., uterine sarcomas) remain challenging, particularly before surgery.\n\nUltrasound is the first-line tool for evaluating fibroids, with specific features (e.g., shape, vascularity) helping distinguish benign from suspicious lesions. The MUSA guidelines standardize ultrasound terminology for myometrial assessments. Current treatment options vary based on symptoms and malignancy risk. Among pharmacologic options, the combination of relugolix, estradiol, and norethisterone has shown efficacy in reducing bleeding and pain in symptomatic fibroids, with a favorable safety profile. However, its impact on fibroid morphology and ultrasound appearance is not yet well understood.",[61,126,127,26],"Uterine Leiomyomas","Uterine Hemorrhage",[129,130,131,132,133,134],"myomas","uterine bleeding","fibroids","relugolix","ormonal therapy","smooth muscle cells tumor","RECRUITING","2025-08-15",{"date":138,"type":38},"2025-08-17",{"date":140,"type":38},"2025-05-02",{"date":142,"type":21},"2027-05-02",{"name":44,"class":45},{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":55,"minAge":18,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":46},"100333698","analysis-and-optimization-of-predictive-and-therapeutic-models-in-uterine-neoplasms-100333698","NCT03624712","Analysis and Optimization of Predictive and Therapeutic Models in Uterine Neoplasms","Prospective, Tricentric Open Trial on the Analysis and Optimization of Predictive and Therapeutic Models in Uterine Neoplasms","Inclusion Criteria:\n\n* Confirmed uterine malignancy ( cervical cancer, endometrial cancer, sarcoma)\n* If operable: surgical primary therapy: laparoscopic\u002Frobot-assisted or open radical gyneco-oncological surgery\n* Written consent\n* Willingness and ability to participate in all study-specific procedures\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Severe and acute general disease in the last 4 weeks\n* Acute or chronic psychiatric disorders\n* Other factors questioning study participation (e.g. acute psychosocial stress, insufficient understanding of nature and consequences of the study, inadequate skills of the German language)",{"count":152,"type":21},580,"Evaluation of clinical, therapeutic and prognostic relevance of new experimental results as well as optimization of therapeutic models and development of a new algorithm for therapeutic plan and therapy in patients with uterine neoplasm",[26],"2025-01-15",{"date":157,"type":38},"2025-01-17",{"date":159,"type":38},"2012-01",{"date":161,"type":21},"2027-12",{"name":163,"class":45},"University Hospital Tuebingen",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":55,"minAge":170,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":174,"phases":175,"briefSummary":177,"conditions":178,"keywords":187,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":200},"100367261","research-project-on-reminders-and-self-sampling-can-increase-participation-in-gynecology-cell-sampling---preventive-examination-against-cervical-cancer-100367261","NCT04061967","Research Project on Reminders and Self-Sampling Can Increase Participation in Gynecology Cell Sampling - Preventive Examination Against Cervical Cancer.","Inclusion Criteria:\n\n* Women resident in Region Skane who either: 1) have had glandular cell transformation that has not been followed-up, 2) are older than 65 years and have had cell transformation that has not been followed-up or who have not participated in screening during the last 10 years, 3) women who have not been screened for more than 15 years.\n\nExclusion Criteria:\n\n* No exclusion except those who do not consent.","33 Years","75 Years",{"count":173,"type":21},20000,"INTERVENTIONAL",[176],"NA","Prevention of cervical cancer with cervical screening is one of the most successful screening activities in medicine. In Sweden, screening was implemented in the 1960s and has since prevented tens of thousands of women from having cervical cancer. Individual invitations to screening result in increased attendance therefore evaluating strategies for reaching women through invitations is particularly valuable. Women who regularly attend screening following an invitation reduce their risk of cervical cancer by as much as 90%. Of the women who are diagnosed with cervical cancer (about 550 women per year in Sweden), as many as 38% did not participate in the screening. Invitations for screening are sent to the entire population in Sweden aged 23-70. The current coverage of screening is 82.9%, which represents the proportion of women ages 23-70 who attend according to recommendations. In addition, many women are sporadic attenders who reduce their risk for cancer somewhat. The highest cancer risk is seen among those women who have never participated as well as women who have had a history of precancerous lesions or HPV infection but have not been followed-up. Cervical cancer is the first form of cancer for which there are approved molecular screening tests (HPV test). Unlike the older screening method (cytology), self-collected samples can be analyzed for HPV (the analysis method is so sensitive that it does not matter if the sample is not optimally taken).\n\nInvitations and reminders about cervical screening are sent by letter to the woman's home address (about 3 million letters per year in Sweden). This strategy results in a waste of resources and has a negative environmental impact. Regarding reminders, we have seen in previous research that the effect is not optimal. When sending a physical reminder letter to women who have not participated in more than 10 years (current routine), only 2% of the women invited came for sampling. Reminders with SMS are now standard for many businesses in society, such as car testing or dental appointments. It is inexpensive, saves the environment and there are studies that suggest it is more effective than sending physical letters. In this study, we intend to investigate whether SMS reminders, electronic letters, and physical letters for screening lead to increased participation and thus to a higher proportion of detected, treatable precursors of cervical cancer compared to before.",[99,179,26,180,181,182,183,184,185,186],"Uterine Cervical Neoplasm","Genital Neoplasm","Genital Neoplasm, Female","Uterine Diseases","Genital Diseases, Female","Neoplasms by Site","Neoplasms","Uterine Cervical Disease",[188,189,190],"participation","self sampling","screening","2025-01-10",{"date":193,"type":38},"2025-01-14",{"date":195,"type":38},"2019-08-19",{"date":197,"type":21},"2030-06-01",{"name":199,"class":45},"Karolinska Institutet",6,{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":55,"minAge":18,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":46},"100575607","evaluation-of-toxicity-and-outcomes-of-different-therapeutic-strategies-in-patients-with-uterine-neoplasms-100575607","NCT06774482","Evaluation of Toxicity and Outcomes of Different Therapeutic Strategies in Patients With Uterine Neoplasms","Evaluation of Toxicity and Outcomes of Different Therapeutic Strategies in Patients With Uterine Neoplasms Treated With Radiotherapy at the Sant'Orsola Polyclinic in Bologna.","Inclusion Criteria:\n\n* Female patients, aged ≥ 18 years, with a new or previous diagnosis of malignant uterine neoplasm, starting from 01\u002F01\u002F2000, treated at the Radiotherapy Unit of the Sant'Orsola Polyclinic\n* Obtaining informed consent\n\nExclusion Criteria:\n\n* Patients with a new or previous diagnosis of malignant uterine neoplasm who choose not to undergo radiation treatment at the Radiotherapy Unit of the Sant'Orsola Polyclinic",{"count":209,"type":21},3000,"The single-center observational study aims to collect data related to the radiation treatment of uterine neoplasms. The purpose of the study is to systematically gather data on radiation treatment in uterine neoplasms in order to evaluate tumor response and potential toxicity in relation to dosages, fractionation, and techniques used, as well as the combination with other therapies and the characteristics of the disease.\n\nAdditionally, collecting data on both the characteristics of the disease and patients' comorbidities in a large sample may allow for the evaluation of any possible correlation with radiation-induced toxicities, with the aim of being able to predict and prevent them in a personalized manner in the future.\n\nTherefore, the study's goal is to evaluate tumor response and any potential toxicity after radiotherapy treatment in relation to treatment settings, dosages, and techniques used, both for new diagnoses and for cases already diagnosed and treated from 01\u002F01\u002F2000 onwards at the Radiotherapy Unit of Sant'Orsola-Malpighi Polyclinic.\n\nThe structured collection of data necessary for the evaluation of the objectives will cover the observation period from 01\u002F01\u002F2000 to 15\u002F12\u002F2030, for a total of approximately 5000 patients.",[26],"2025-01-08",{"date":193,"type":38},{"date":215,"type":38},"2021-05-19",{"date":217,"type":21},"2030-12-31",{"name":219,"class":45},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":55,"minAge":18,"maxAge":228,"enrollmentInfo":229,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":231,"conditions":232,"keywords":238,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":247,"locationsCount":46},"100457918","retrospective-study-of-brachytherapy-100457918","NCT05242861","Retrospective Study of Brachytherapy","A Retrospective Study of Brachytherapy in Gynecological Cancers","RetroBT","Inclusion Criteria:\n\n* 18 - 80 female\n* Underwent brachytherapy\n* With gynecological cancer\n\nExclusion Criteria:\n\n* Refusal to enter this trial","80 Years",{"count":230,"type":21},300,"Brachytherapy for gynecological cancers will be studied retrospectively.",[233,234,26,235,236,25,237],"Brachytherapy","Uterine Cervical Neoplasms","Vulvar Cancer","Vaginal Cancer","Gynecologic Neoplasm",[233,99,63,236,235,239,240],"Image Guided","3D Print","2022-02-06",{"date":243,"type":38},"2022-02-16",{"date":245,"type":21},"2022-02-20",{"date":111,"type":21},{"name":248,"class":45},"Zhejiang Cancer Hospital"]